Amgen OA-ANZBMS Clinical Grant awarded to Dr Cat Connaughton
IHA Research Fellow Dr Catherine Connaughton was recently awarded the Amgen OA-ANZBMS Clinical Grant for 2017. The awards were announced and presented at the annual Australian & New Zealand Bone and Mineral Society Conference in Brisbane on Tuesday 20th June.
Quality of life is reduced for at least 12-18 months after fracture. The grant Catherine received titled Understanding health and community services that improve recovery from fracture in older adults will serve to identify services that have evidence of assisting in the return of quality of life, and are tailored to reflect specific needs that vary by fracture site, age, sex and socio-demographic groups. The results of the research will benefit the 141,000 Australians who sustain fragility fracture(s) each year.
The total annual cost of treatment for fractures in Australia is $2.1 billion (Watts, Sanders et at, 2013). These costs include emergency services, hospital and outpatient departments, and community services. Cost and impact of fractures on quality of life can be reduced by incorporating a person-centred approach into fracture management plans, addressing problems that commonly arise from the fragmented service provision.
The Amgen OA-ANZBMS Clinical Grant will allow IHA researchers Dr Catherine Connaughton, Professor Kerrie Sanders, and Dr Lucy Busija to use data from over 6000 patients worldwide to identify service use associated with a more rapid improvement in quality of life, facilitate more cost-effective use of healthcare and community services, and reduce the burden of fragility fracture for the individual.